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illiam E. Hellenbrand, MD*
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OBJECTIVES We sought to review and report initial and one-year efficacy and safety results of the
multicenter USA Amplatzer ductal occluder (ADO) device trial.
BACKGROUND Transcatheter closure of a moderate to large patent ductus arteriosus (PDA) using conven-
tional techniques is challenging. The ADO can close a PDA up to 12 mm in diameter.
METHODS From September 1999 to June 2002, 484 patients were enrolled in 25 U.S. centers. Forty-five
(9%) of 484 patients did not have ADO implantation, because the PDA was too small or
because of elevated pulmonary resistance. The median age of the patients at catheterization
was 1.8 years (range 0.2 to 70.7 years), and weight was 11 kg (range 4.5 to 164.5 kg).
RESULTS The median PDA minimal diameter was 2.6 mm (range 0.9 to 11.2 mm); 76 (17%) of 439
were larger than 4.0 mm. Median pulmonary artery mean pressure was 20 mm Hg (range 7
to 80 mm Hg). The ADO was implanted successfully in 435 (99%) of 439 patients, with a
median fluoroscopy time of 7.1 min (range 2.9 to 138.4 min). Angiographic demonstration
of occlusion was seen in 329 (76%) of 435. This increased to 384 (89%) of 433 on
post-catheterization day 1, with occlusion documented in 359 (99.7%) of 360 at one year. At
the last evaluation in all patients at any time, PDA closure was documented in 428 (98%) of
435 patients. There have been two cases of partial left pulmonary artery occlusion after ADO
implantation and no cases of significant aortic obstruction.
CONCLUSIONS Moderate to large PDAs can be effectively and safely closed using the ADO device, with
excellent initial and one-year results. This device should obviate the need for multiple coils or
surgical intervention for these defects. (J Am Coll Cardiol 2004;44:513–9) © 2004 by the
American College of Cardiology Foundations
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(ortsmann et al. (1) reported the first transcatheter closure
f the patent ductus arteriosus (PDA) in 1971. Subse-
uently, Rashkind and Cuaso (2) reported on the use of the
ashkind double-umbrella occluder device to close a PDA.
he Rashkind device was later modified, and ultimately,
ther transcatheter techniques of PDA closure have been
ntroduced and applied clinically with good results, such as
ouble-umbrella devices (e.g., Bard occluder), coil emboli-
ation, and Grifka bag devices (3–12). Although efficacious
or the closure of smaller PDAs, most of these closure
echniques have the disadvantages of having somewhat
igher than acceptable residual shunt percentiles or being
echnically quite cumbersome to implant when applied to
he closure of moderate to large PDAs.
The Amplatzer ductal occluder (ADO) is a novel nitinol
rame device that has been adapted from the previously
escribed Amplatzer atrial septal defect device (13,14). The
uperelastic nitinol allows for great variability in device
From the *Children’s Hospital of New York, Presbyterian Hospital, Columbia
niversity, New York, New York; and †University of Chicago Children’s Hospital,
niversity of Chicago, Pritzker School of Medicine, Chicago, Illinois. Dr. Hijazi is
paid consultant to AGA Medical, the manufacturer of the Amplatzer PDA duct
ccluder device.
Manuscript received September 7, 2003; revised manuscript received January 26,r004, accepted March 2, 2004.hape and size and also allows for great adaptability to a
ariety of ductal shapes and sizes (Fig. 1). The device is
acked with polyester fabric to aid in thrombosis and,
herefore, ultimate ductal closure. Although the device has
een demonstrated to be safe and efficacious in smaller
tudies, thus far there have been no multicenter trials
eviewing device safety and efficacy at one-year follow-up
15,16). Therefore, this study was undertaken to review
oth the safety and efficacy of the ADO for the treatment of
oderate to large PDAs immediately after implantation and
gain at one-year follow-up.
ETHODS
rom September 1999 to June 2002, 25 centers in 18 states
n the U.S. enrolled a total of 484 patients into this study in
nonrandomized fashion (Appendix). The protocol used
or this trial was approved by the Institutional Review Board
f each participating center. Enrolled patients had angio-
raphic or echocardiographic evidence of a PDA. The other
nclusion criterion for the study was body weight 5 kg.
he exclusion criteria for this study were pulmonary vascu-
ar resistance above 8 indexed Wood’s units or Rp/RS
pulmonary vascular resistance divided by systemic vascular
esistance) 0.4, an additional noncardiac abnormality that
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USA Amplatzer PDA Occlusion Device Trial August 4, 2004:513–9ight affect health in the next two years, inferior vena cava
r pelvic vein thrombosis, sepsis or a history of repeated
ulmonary infection, intracardiac thrombi on echocardiog-
aphy, inability to obtain informed consent, or complex
ssociated congenital heart disease.
Baseline noninvasive data were obtained by physical
xaminations, electrocardiography, echocardiography, and
hest radiography. During cardiac catheterization, angio-
raphic and hemodynamic data were obtained before and
fter closure. After closure, repeat noninvasive data were
btained at one day (pre-discharge), six months, and one
ear after device implantation. Data were collected at the
articipating clinical sites and recorded on case-report
orms, which were sent to a central data processing center.
onitoring visits were carried out by trained AGA Medical
linical monitors, and a Data Safety Monitoring Board was
sed to review and adjudicate all reported adverse events.
dditionally, an independent Echocardiography Review
oard was used to review a subset (40% to 50%) of
chocardiographic studies, as well as gradient data.
The technique of implantation in the catheterization
aboratory was standardized. To summarize, a right and left
eart catheterization was initially performed. After baseline
emodynamic measurements, an angiogram was obtained in
iplane projections in order to profile the ductus (Fig. 2A).
he catheter was typically positioned in the descending
orta for this angiogram. Angiographic measurements of
he ductus at its narrowest and widest segments, as well as
ts length, were made in the lateral plane. Next, an end-hole
atheter was passed prograde through the ductus to the
escending aorta, and a guide wire was placed via this
Abbreviations and Acronyms
ADO  Amplatzer ductal occluder
PDA  patent ductus arteriosus
LPA  left pulmonary artery
MPA  main pulmonary artery
igure 1. The Amplatzer duct occluder device. In this example of a 10/8
evice, the “10” refers to the aortic end of the device, and “8” refers to the
ulmonary end. The retention disk on the aortic end is generally 4 to 5 mmtarger in diameter than the aortic end’s diameter.atheter, with its end in the descending aorta. An introducer
elivery sheath was then exchanged transvenously over this
uide wire to the descending aorta. Devices are manufac-
ured in several sizes. In general, a device was chosen so that
he diameter of the pulmonary arterial end of the device was
2 mm larger than the narrowest diameter of the ductus
usually the pulmonary end of the ductus). Thus, the devices
sed were 5/4 (3%), 6/4 (45%), 8/6 (41%), 10/8 (6%), 12/10
3%), 14/12 (1%), and 16/14 (1%). As demonstrated in
igure 1, the first number refers to the diameter of the
evice adjacent to the retention disk, and the second
umber to the diameter at the attachment point. Once
oaded on the delivery cable, the device is delivered by
nitially deploying only the retention disk and pulling it
rmly against the orifice of the ductus and embedding it
nto the ductal ampulla. The rest of the device is then
ncovered within the PDA. An aortogram was then ob-
igure 2. (A) Lateral angiogram of a patient with a ductus measuring 4
m in diameter at its narrowest portion. (B) Lateral angiogram of same
atient after implantation of an 8/6 device in the ductus, demonstrating a
mall residual “smoke”-like shunt. This shunt completely closed on
ost-catheterization day 1.ained to confirm appropriate positioning of the device. If
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August 4, 2004:513–9 USA Amplatzer PDA Occlusion Device Trialhe device appeared in the appropriate location and was not
rojecting into either the aorta or left pulmonary artery
LPA) to a significant degree, the device was released in the
uctus. After release of the device, repeated hemodynamic
easurements were made, including a direct pullback gra-
ient from the LPA to main pulmonary artery (MPA) and
rom the ascending to descending aorta to evaluate any
bstruction. A repeated angiogram was then obtained to
onfirm appropriate positioning of the ADO and to evaluate
ny residual left to right shunting (Fig. 2B).
ESULTS
uring the study period, 484 patients were taken to the
ardiac catheterization laboratory for potential enrollment
n the study. Of this group, 45 patients did not undergo
mplantation and were excluded from post-implantation
nalysis. In 43, the PDA was considered so small as to be
ore easily embolized with Gianturco coils and was suc-
essfully closed in this manner. Two patients had significant
ulmonary artery hypertension and elevated pulmonary
ascular resistance and, therefore, did not undergo ductal
losure. As a result, ultimately, 439 patients had ADO
mplantation attempted and were enrolled in this study for
nalysis. Sixty-eight percent of patients were female. The
edian age at catheterization in the patient group was 1.8
ears (range 0.2 to 70.7 years), and the median weight was
1 kg (range 4.5 to 164.5 kg). Physical examination dem-
nstrated 412 (94%) of 439 to have a continuous murmur,
nd 43 of 437 were noted to clinically demonstrate signs of
ongestive heart failure. In patients in whom a chest
adiograph was obtained before cardiac catheterization,
ardiomegaly was observed in 223 (58%) of 383. The
ssessment of chest radiographs was made by the treating
ardiologist, who was not blinded to the patient’s disease.
atheterization data before closure. Pre-implantation
Figure 3. Flow chart of early anatheterization data were obtained on all patients. The pedian of the mean pressure was 20 mm Hg (range 7 to
0). Using superior vena cava samples as mixed venous
aturations, the median Qp/Qs (pulmonary flow divided by
ystemic flow) ratio in the study group was 2:1. Gradients
ere measured from the MPA to LPA, with no gradient
een in 134 (31%) of 435 patients and a median peak systolic
radient of 4 mm Hg (range 1 to 30 mm Hg) seen in 301
69%) of 435 patients. Pre-implantation gradients across the
ortic arch were also measured. No gradient was recorded in
21 (74%) of 433 patients, and a median gradient of 3 mm
g (range 1 to 20 mm Hg) was measured in 112 (26%) of
33.
The anatomy of the PDA was classified angiographically
ased on the categories first described by Krichenko et al.
17). There were 243 (55.4%) of 439 PDA type A-1, 52
11.8%) of 439 type E, 49 (11.2%) of 439 type A-2, 36
8.2%) of 439 type A-3, and 35 (8.0%) of 439 type C. The
est were relatively evenly distributed among the remaining
natomic subtypes. In the lateral view, the median smallest
iameter measured angiographically was 2.6 mm (range 0.9
o 11.2 mm), and the median length of the ductus from
ulmonary to aortic end was 7.0 mm (range 1.5 to 35 mm);
6 (17%) of 439 were larger than 4.0 mm at their smallest
ngiographic diameter measured in the lateral view.
atheterization laboratory after closure. Implantation
as successful in 435 of the 439 patients, and these patients
onstitute the main study group (Fig. 3). Complete angio-
raphic closure was documented at the end of the procedure
n 329 patients (76%). A residual shunt was present in 106
atients (24%), with 70 (66%) being classified as a “smoke”
like shunt (left-to-right shunt present with no jet seen), 32
30%) with a “small” shunt (left-to-right shunt present with
jet 2 mm in diameter, and 4 (4%) with a “large” shunt
left-to-right shunt present with the jet 2 mm).
After device deployment, there was no change in the
st-catheterization day 1 results.ercentages of patients who had a gradient from the
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USA Amplatzer PDA Occlusion Device Trial August 4, 2004:513–9scending to descending aorta. In the 431 patients in whom
uch gradients were measured according to protocol, there
as no gradient recorded in 330 (76.6%), whereas 101
23.4%) had a gradient seen (p  NS vs. pre-deployment).
n the 101 of 431 patients in whom there was a post-
eployment gradient recorded, the median gradient was 4
m Hg (range 1 to 19 mm Hg). Only a single patient had
gradient above 15 mm Hg after device implantation
unchanged from pre-device implantation) in the catheter-
zation laboratory. There was no pressure difference between
he LPA and MPA recorded on pullback after device
mplantation in 192 (45.8%) of 410 patients, and 227
54.2%) had a median gradient of 3 mm Hg (range 1 to 24
m Hg). Only eight patients had gradients recorded over
0 mm Hg. All eight had pre-implantation gradients, and
nly one in this group had an increase above 10 mm Hg
increase of 12 mm Hg).
As noted earlier, a device was not permanently implanted
n four patients in this series. One patient had the device
rotruding far into the MPA and the device was therefore
etrieved and the PDA was then coil occluded. The second,
mall patient had a large ductus, and the device embolized
o the pulmonary artery. This device was surgically retrieved
t the time of ductal surgical ligation. The third patient had
o ductal ampulla and therefore had no place for the ADO
etention disk. As a result, the device was not released from
he delivery cable and was removed. The fourth patient’s
DO protruded too far into the aorta. As a result, the
evice was retrieved at the time of catheterization, and the
uctus was later surgically divided.
The median procedural time during implantation was 32
in (range 15 to 269). The median fluoroscopy time was
.1 min (range 2.9 to 138.4). The majority (79%) of ducts
ere closed using a 6F (range 5F to 8F) transvenous delivery
heath.
ost-procedural results: post-catheterization day 1. Echo-
ardiograms and physical examinations were documented
or the majority of patients who underwent ADO implan-
ation on post-catheterization day 1. At time of discharge,
here was complete closure of the ductus seen on echocar-
iography in 384 (89%) of 433 patients. In the remaining 49
11%), there were no large shunts seen: 20 (41%) of 49 were
moke (defined as low-velocity flow with no obvious “jet”
esion) and 29 (59%) of 49 were small on color-flow
Figure 4. Outcome of patients with reoppler interrogation. Echocardiographic interrogation of uhe aortic arch demonstrated no gradient in 176 (68%) of
60 patients and a median gradient of 8 mm Hg (range 1 to
9 mm Hg) in 84 (32%). Of this small group with
ost-catheterization aortic gradients on echocardiography,
nly two patients had recorded echocardiographic gradients
bove 20 mm Hg. One of the two had similar pre- and
ost-catheterization gradients. The other patient had an
ncrease in gradient from 0 to 29 mm Hg. When reviewing
re-discharge pulmonary artery gradient data, there was no
radient seen in 230 (62%) of 371 patients, and a median
radient of 9 mm Hg (range 1 to 34 mm Hg) was seen in
41 (38%). Of these patients with a gradient, 27 (19%) of
41 had gradients on echocardiography above 10 mm Hg.
nly three of these patients had a gradient above 30 mm
g (maximal gradient of 34 mm Hg recorded).
ost-procedural results: six-month and one-year follow-up
ata. As noted earlier, at hospital discharge, there were 49
11%) of 433 patients implanted who had a residual shunt
Fig. 4). Of these 49 patients, there has been no follow-up
n six patients either at six or 12 months. However, among
he remaining 43 patients, there has been documentation at
ix months of complete closure on echocardiography in 41
atients. In the two remaining patients, there was a “small”
hunt remaining. At one-year follow-up, there has not yet
een follow-up on one of the two patients with “small”
emaining shunts at six months. Thus, at the last evaluation
n all patients at any time, there has been documentation of
omplete PDA closure in 428 (98%) of 435 patients. It
hould be noted that in the 341 patients who were clinically
valuated at six-month follow-up, 340 (99.7%) of 341 did
ot have a residual continuous murmur. At one-year follow-
p, of the presently eligible 435 patients, 370 (85%) have
hus far been evaluated (Fig. 5). Of this group, 369 (99.7%)
f 370 do not have a continuous murmur and 359 (99.7%)
f 360 have echocardiographic documentation of no residual
eft-to-right shunting.
On reviewing pressure gradients on echocardiography at
ix months, there was no gradient across the aortic arch in
26 (74%) of 306 patients evaluated, and a small median
radient of 5 mm Hg (range 1 to 21 mm Hg) was seen in
0 (26%). Only a single patient had a gradient over 20 mm
g (i.e., 21 mm Hg). This patient did not have a gradient
cross the aortic arch during post-implantation hemody-
amic evaluation at catheterization. At six-month follow-
l shunts at the end of catheterization.siduap, 217 (67%) of 323 patients had no gradient from the
M
h
O
r
2
w
fl
m
1
f
r
y
g
f
v
T
s
o
o
fl
(
C
T
t
t
e
r
s
d
o
T
I
w
c
w
s
i
n
s
a
s
(
m
d
o
o
s
l
T
s
q
g
p
v
a
o
p
d
s
t
l
(
D
S
“
h
s
o
T
o
e
h
m
k
c
T
M
M
517JACC Vol. 44, No. 3, 2004 Pass et al.
August 4, 2004:513–9 USA Amplatzer PDA Occlusion Device TrialPA to LPA on echocardiography, and 106 (33%) of 323
ad a median gradient of 7 mm Hg (range 1 to 38 mm Hg).
f these, 18 (17%) of 106 had a gradient on echocardiog-
aphy over 10 mm Hg, with only two of these being above
0 mm Hg. A single patient had a gradient of 38 mm Hg
ith a quantitative lung perfusion scan demonstrating 31%
ow to the affected lung. A repeated echocardiogram six
onths later showed marked diminution in the gradient to
1 mm Hg without further intervention.
At one year follow-up echocardiographic evaluation, thus
ar, pressure gradients have been similar or better than those
ecorded at six months, and no patient has a gradient at one
ear above 20 mm Hg. Two of 359 patients have had a
radient of 20 mm Hg on echocardiography recorded
rom the MPA to LPA (none over 29 mm Hg).
A separate analysis of patients with a PDA of 4 mm
ersus those with a PDA under this size was performed.
he incidence of complete vessel closure at one year was the
ame at one year (p  NS). There were also no differences
bserved in the incidences of LPA stenosis, aortic arch
bstruction, or other complications (p  NS). Finally, the
uoroscopy times were similar between the two subgroups
p  NS).
omplications. Procedural complications are reviewed in
able 1. Serious procedural complications were rare during
his study. There were two device embolizations noted in
his study group. As noted earlier, one patient had device
Figure 5. Flow chart of one-year results after catheterization.
able 1. Procedural Complications (n  439)
ajor adverse events
Death 1
Device embolization requiring surgery 1
Device embolization with percutaneous retrieval 1
Partial obstruction of pulmonary artery 2
Pseudoaneurysm 2
Loss of femoral pulse 1
Bleeding requiring transfusion 2
Hypertension 1
Total major events 10 (2.3%)
inor adverse events
Hematoma of groin 7
Arrhythmia requiring medication or cardioversion 2
Loss of peripheral pulse 6
Other 7
Total all major and minor events 31 (7.1%) bmbolization to the pulmonary artery requiring surgical
emoval and ductal ligation, without an adverse event. A
econd patient had embolization of the device to the
escending aorta. This was successfully retrieved percutane-
usly, and a larger device was then successfully deployed.
here were two episodes of bleeding requiring transfusion.
n one case, there was difficulty unscrewing the device, as
ell as significant bleeding from the sheath. In the second
ase, there was a pulse loss requiring thrombolytic therapy,
hich resulted in significant bleeding at the catheterization
ite. Laryngospasm was seen in one patient after catheter-
zation, which required re-intubation and aggressive pulmo-
ary toilet with no untoward effect. One patient required
urgical repair of a femoral artery false aneurysm and
rteriovenous fistula after catheterization.
Reviewing minor procedural complications, there were
even groin hematomas (1.6%), six temporary pulse losses
1.4%), two cardiac arrhythmias requiring cardioversion or
edication (0.5%), and seven other minor assorted proce-
ural complications (1.6%).
On follow-up, there were two cases of partial obstruction
f the LPA seen (gradient of 20 mm Hg on echocardi-
graphy). In one case, a peak velocity of 2.9 to 3.0 m/s was
een in the LPA at six-month follow-up, with a quantitative
ung perfusion scan demonstrating 21% flow to the left lung.
he second case demonstrated a gradient of 38 mm Hg at
ix-month follow-up and 31% flow to the left lung with
uantitative lung perfusion testing. As noted earlier, the
radient recorded fell to 11 mm Hg at one-year follow-up.
There was a single death in this series. A 15-month-old
atient with partial trisomy 18 and a bi-commissural aortic
alve underwent successful closure of a PDA. Five months
fter implantation, she died of respiratory distress related to
verwhelming sepsis with Acinetobacter baumannii. The
atient’s family elected for no treatment, and the patient
ied four days after diagnosis. Thus, the incidence of
erious, major adverse events (e.g., death, device emboliza-
ion, bleeding requiring transfusion, hypertension, pulse
oss, partial LPA obstruction, pseudoaneurysm) was 2.3%
10 of 439).
ISCUSSION
ince 1939, surgical management of the PDA has been the
gold standard” against which all other techniques of closure
ave been measured (18,19). Mavroudis et al. (19) demon-
trated a 100% success rate for PDA ligation and/or division
ver a 46-year period in a single institution (n  1,108).
his group had a morbidity rate of 4.4%, an average length
f stay of 2.8 days, and 0% mortality. In recent decades,
fforts to perfect a transcatheter approach to ductal closure
ave been extensive, and there have been a number of
ethods suggested, including the Portsmann plug, Rash-
ind device, and, more recently, Gianturco embolization
oils (1–12). The major goal of all of these efforts has clearly
een to avoid surgery and its rare but significant attendant
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USA Amplatzer PDA Occlusion Device Trial August 4, 2004:513–9isks. All of these transcatheter techniques have been effi-
acious, although each has had problems related either to
he length of procedure (and prolonged fluoroscopy times),
arge delivery systems (and potential risks to the femoral
eins and arteries), creation of gradients to the LPA, and,
erhaps most importantly, residual leaks.
The Amplatzer PDA occlusion device was designed to
ddress the aforementioned concerns. As demonstrated in
his multicenter trial, the device is extremely efficacious at
losing not only smaller PDAs but also moderate to large
nes. At one-year follow-up among patients who have been
valuated, there has been 99.7% occlusion documented.
nalyzing these data in another manner, 428 (98%) of 435
atients have had complete PDA occlusion on echocardi-
graphy at their last evaluation. If the four extra patients in
hom a device was placed into the body but not left
econdary either to malposition or too large a size are
ncluded in the denominator, assuming those patients have
pen PDAs (which is not, in fact, true secondary to
ost-catheterization surgery), the success rate at one year
ould be 97.5% (428 of 439). Six of the remaining seven
atients in whom PDA closure has not been documented
ave not actually been assessed at 12-month follow-up, and
t is certainly conceivable that the residual shunt in these
atients might have closed during the follow-up period.
iven that all but one of the ducts with one-year follow-up
hat were not closed on post-catheterization day 1 have
losed later, this assertion is certainly not without merit.
These findings are most impressive when reviewing both
he size and shapes of the ducti closed in this study. As
oted earlier, the median ductal diameter was 2.6 mm, and
6 were over 4 mm in diameter. Additionally, virtually every
hape of ductus that has been previously described was seen
nd closed in this trial using the ADO. Thus, this device has
roven extremely adaptable to a number of ductal anatomic
ubstrates and is also efficacious at closing even very large
ucts that previously were nearly impossible to close using
ther transcatheter techniques. It should also be noted that
he majority of PDAs in this trial were closed using only a
F venous sheath.
Use of the ADO was safe. As noted, there was a serious
omplication rate of 2.3%, with a single death that was
nrelated to device implantation and occurred over five
onths after ductal closure. Perhaps the most concerning
orbidity of this device would be LPA and aortic arch
bstruction. In this study, there was only a single patient
ho developed a gradient across the aortic arch of 20 mm
g at one year. This patient, in retrospect, had a narrowed
ortic arch before catheterization and also a small mitral
alve, consistent with Shone’s syndrome. Had these factors
een appreciated more clearly, this patient would have likely
een excluded from the study and analysis, as the develop-
ent of an aortic gradient may have been unrelated to
evice placement. Although a small number of patients have
ad low gradients recorded on echocardiography to the
PA after device implantation, of concern would be the twoatients in whom a gradient above 20 mm Hg developed.
his was an infrequent complication, and analysis of this
roblem is difficult, as a significant number of patients with
DAs have small gradients to the LPA before PDA
cclusion. Additionally, there is little to no data on the
ncidence of LPA narrowing observed after surgical ligation
r division of the PDA, making a comparison with other
urgical techniques difficult. Because of the small numbers
f significant LPA obstructions observed, conclusions as to
he etiology or means of preventing this complication are
ot obvious from these data. However, in general, it would
eem likely that use of a large or oversized device in a small
atient might be a risk factor for this complication. Further
esearch or analysis of this complication may be indicated,
nd the subsequent development of a newer device with a
ecessed aortic retention disk may prevent this problem in
he future.
Although length of stay was not formally reviewed in this
tudy, the vast majority of patients were hospitalized for 24 h.
his would compare quite favorably with any surgical or
ranscatheter literature on this topic. The median fluoroscopy
ime was 7.1 min, and the median procedural time was 32 min,
hich both compare favorably with previous catheterization
escriptions. When considering that a large number of ducti
losed in this study were moderate to large in size, these
uoroscopy and procedural times are indeed short.
onclusions. These findings have demonstrated that the
DO can safely and effectively close moderate to large PDAs
ith excellent early and one-year results. Additionally, even
DAs with residual early leaks appear to close within six
onths to one year. With the introduction of this device,
irtually all sized PDAs (up to 11 mm diameter) can now be
losed safely and effectively using transcatheter techniques.
eprint requests and correspondence: Dr. Robert H. Pass,
ivision of Pediatric Cardiology, Department of Pediatrics, Pres-
yterian Hospital, Columbia University, 3959 Broadway, 2 North,
ew York, New York 10032. E-mail: Pediheart@aol.com.
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